Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
AirDuo™ RespiClick® (fluticasone/salmeterol) – New drug approval
January 30, 2017 – Teva announced the FDA approval of AirDuo RespiClick (fluticasone/salmeterol), for the treatment of asthma in patients aged 12 years and older.
